Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Satsuma Pharmaceuticals (STSA : NSDQ)

• Company Description    Satsuma Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It develops novel therapeutic products for the acute treatment of migraine. The company's product consists of STS101, which are in clinical stage. Satsuma Pharmaceuticals Inc. is based in San Francisco, United States. Number of Employees: 25

• Price / Volume Information    Yesterday's Closing Price: $1.07 Daily Weekly Monthly 20 Day Moving Average: 475,697 shares Shares Outstanding: 33.15 (millions) Market Capitalization: $35.47 (millions) Beta: 0.10 52 Week High: $8.08 52 Week Low: $0.59 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 1.90% -1.95% 12 Week 13.83% 5.67% Year To Date 18.89% 8.14%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 400 OYSTER POINT BOULEVARD SUITE 221 - SOUTH SAN FRANCISCO,CA 94080 USA ph: 650-410-3200 fax: - cdavis@lifesciadvisors.com http://www.satsumarx.com

• General Corporate Information    Officers John Kollins - President and Chief Executive Officer Tom O'Neil - Chief Financial Officer Elisabeth Sandoval Little - Director Heath Lukatch - Director Ken Takanash - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 80405P107 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/23 Next Expected EPS Date: 08/08/23 Share - Related Items Shares Outstanding: 33.15 Most Recent Split Date: (:1) Beta: 0.10 Market Capitalization: $35.47 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.25 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.82 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/08/23

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.94 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 36.73% vs. Previous Quarter: 55.71% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/23 - -115.24 12/31/22 - -102.13 09/30/22 - -75.98 ROA 03/31/23 - -102.26 12/31/22 - -92.24 09/30/22 - -69.67 Current Ratio 03/31/23 - 7.44 12/31/22 - 6.75 09/30/22 - 10.15 Quick Ratio 03/31/23 - 7.44 12/31/22 - 6.75 09/30/22 - 10.15 Operating Margin 03/31/23 - - 12/31/22 - - 09/30/22 - - Net Margin 03/31/23 - - 12/31/22 - - 09/30/22 - - Pre-Tax Margin 03/31/23 - - 12/31/22 - - 09/30/22 - - Book Value 03/31/23 - 1.14 12/31/22 - 1.41 09/30/22 - 2.16 Inventory Turnover 03/31/23 - - 12/31/22 - - 09/30/22 - - Debt-to-Equity 03/31/23 - 0.00 12/31/22 - 0.00 09/30/22 - 0.00 Debt-to-Capital 03/31/23 - 0.00 12/31/22 - 0.00 09/30/22 - 0.00

Powered by Zacks Investment Research ©